Breaking News

George Clinical to Support Hummingbird’s Phase 1 Oncology Trials

Will provide its full-service clinical research services for Hummingbird's anti-HER3 drug trials.

George Clinical, a global CRO, initiated preparations in Australia for two Phase 1b oncology trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing its full-service clinical research services for the Hummingbird Bioscience-sponsored trials. Hummingbird Bioscience, a data-driven precision biot...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters